Int Forum Allergy Rhinol:莫米松在培养的上皮细胞中吸收情况研究

2019-11-06 AlexYang MedSci原创

外用莫米松治疗经常使用鼻内喷雾剂,用于药物洗脱支架上,并由专业的药店配制而成。典型的鼻窦冲洗使用240毫升的缓冲盐水溶解1.2毫克莫米松,并对鼻腔进行冲洗。莫米松冲洗液快速流过对侧鼻腔或鼻咽,接触时间为5到10秒。然而,关于鼻腔对外用莫米松的吸收率方面还没有相关信息。最近,有研究人员为了确定对莫米松的吸收特性情况,研究人员从2名健康捐赠者中获取了鼻上皮细胞,并在囊膜上将这些细胞分化为成熟的纤毛上皮

外用莫米松治疗经常使用鼻内喷雾剂,用于药物洗脱支架上,并由专业的药店配制而成。典型的鼻窦冲洗使用240毫升的缓冲盐水溶解1.2毫克莫米松,并对鼻腔进行冲洗。莫米松冲洗液快速流过对侧鼻腔或鼻咽,接触时间为5到10秒。然而,关于鼻腔对外用莫米松的吸收率方面还没有相关信息。

最近,有研究人员为了确定对莫米松的吸收特性情况,研究人员从2名健康捐赠者中获取了鼻上皮细胞,并在囊膜上将这些细胞分化为成熟的纤毛上皮。研究人员将莫米松施加到细胞表面,并接触不同的时间,之后使用磷酸缓冲液清洗掉未被吸收的莫米松。之后,研究人员将细胞进行收集并保存在盐酸胍中,并通过高效液相质谱联用分析进行定量。研究发现,平均38分钟时能够达到最大吸收率的50%,最大吸收率发生的时间均值为114分钟。

最后,研究人员指出,他们的数据对鼻腔对莫米松的吸收情况提供了评估参考,并且指出了盐水灌洗时吸收率与接触时间并不匹配。

原始出处:

Nguyen TT, Soma PS, Mascenik T et al. Mometasone absorption in cultured airway epithelium. Int Forum Allergy Rhinol. 21 Oct 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1676077, encodeId=455716e60770c, content=<a href='/topic/show?id=3e7c8e9884c' target=_blank style='color:#2F92EE;'>#莫米松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87988, encryptionId=3e7c8e9884c, topicName=莫米松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31b227313875, createdName=listen327, createdTime=Thu Feb 27 05:36:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329304, encodeId=6d821329304ac, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Nov 08 04:36:00 CST 2019, time=2019-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533904, encodeId=6dcb153390452, content=<a href='/topic/show?id=4be9200308c' target=_blank style='color:#2F92EE;'>#上皮细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20030, encryptionId=4be9200308c, topicName=上皮细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a5d12492718, createdName=lizhou0208, createdTime=Fri Nov 08 04:36:00 CST 2019, time=2019-11-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1676077, encodeId=455716e60770c, content=<a href='/topic/show?id=3e7c8e9884c' target=_blank style='color:#2F92EE;'>#莫米松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87988, encryptionId=3e7c8e9884c, topicName=莫米松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31b227313875, createdName=listen327, createdTime=Thu Feb 27 05:36:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329304, encodeId=6d821329304ac, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Nov 08 04:36:00 CST 2019, time=2019-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533904, encodeId=6dcb153390452, content=<a href='/topic/show?id=4be9200308c' target=_blank style='color:#2F92EE;'>#上皮细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20030, encryptionId=4be9200308c, topicName=上皮细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a5d12492718, createdName=lizhou0208, createdTime=Fri Nov 08 04:36:00 CST 2019, time=2019-11-08, status=1, ipAttribution=)]
    2019-11-08 膀胱癌
  3. [GetPortalCommentsPageByObjectIdResponse(id=1676077, encodeId=455716e60770c, content=<a href='/topic/show?id=3e7c8e9884c' target=_blank style='color:#2F92EE;'>#莫米松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87988, encryptionId=3e7c8e9884c, topicName=莫米松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31b227313875, createdName=listen327, createdTime=Thu Feb 27 05:36:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329304, encodeId=6d821329304ac, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Nov 08 04:36:00 CST 2019, time=2019-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533904, encodeId=6dcb153390452, content=<a href='/topic/show?id=4be9200308c' target=_blank style='color:#2F92EE;'>#上皮细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20030, encryptionId=4be9200308c, topicName=上皮细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a5d12492718, createdName=lizhou0208, createdTime=Fri Nov 08 04:36:00 CST 2019, time=2019-11-08, status=1, ipAttribution=)]

相关资讯

Ann Allergy Asthma Immunol:奥洛帕他定/莫米松组合鼻用喷雾能够改善季节过敏性鼻炎症状

GSP301鼻用喷雾是抗组胺药物盐酸奥洛帕他定和皮质类固醇糠酸莫米他松的固定剂量组合,并倾向性的用于季节过敏性鼻炎(SAR)的治疗。最近,有研究人员在一个豚草花粉环境暴露环境(EEC)下,评估了一日一次(QD)或者一日二次(BID)下的效果和安全性。研究是一个随机的、双盲的和双模拟研究,研究人员将SAR患者(年龄在18-65岁)随机等分到GSP301 BID组、GSP301 QD组、AzeFlu组